Anti-CD31 antibody (Ab124432)
CD31, Pecam, Pecam-1, Pecam1, Platelet endothelial cell adhesion molecule, PECAM-1
详细信息
背景信息
Anti-CD31 antibody (ab124432) is a rabbit polyclonal antibody and is validated for use in IHC-P, WB in human, mouse samples. Anti-CD31 antibody (ab124432) has been cited over 87 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality validation processes ensure Anti-CD31 antibody (ab124432) has high sensitivity and specificity. Anti-CD31 antibody (ab124432) has 4 independent reviews from customers. Anti-CD31 antibody (ab124432) specifically detects CD31 (UniProt ID: P16284; Molecular weight: 80kDa) and is sold in 100 µg selling sizes.
文献引用 (114)
Anti-cancer immune priming with β-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-Isoform of B7-H3.
利用新型高亲和力抗体选择性靶向 B7-H3 的 4Ig 同工型，通过 β-放射性配体疗法进行抗癌免疫启动。
In vivo optoacoustic imaging of endothelin receptor expression and treatment response in the hypoxic tumor microenvironment.
利用体内光声成像技术研究缺氧肿瘤微环境中内皮素受体表达和治疗反应。
Inducible Ift88-deficient mice show features consistent with mild pulmonary hypertension.
诱导型 Ift88 缺陷小鼠表现出与轻度肺动脉高压一致的特征。
Macropinocytosis maintains CAF subtype identity under metabolic stress in pancreatic cancer
巨胞饮作用在胰腺癌代谢应激下维持 CAF 亚型特性
Wireless In Situ Catalytic Electron Signaling-Mediated Transcriptomic Reprogramming for Neuron Regeneration via Adaptable Antennas.
通过可适应性天线实现无线原位催化电子信号介导的转录组重编程以促进神经元再生
Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma
肿瘤来源的CCL16通过巨噬细胞ICAM-1受体使肿瘤血管正常化，并增强肝细胞癌的免疫治疗疗效
Cell-selective telomere damage by thiopurine-based oligonucleotide for diffuse large B cell lymphoma immunotherapy
利用硫嘌呤类寡核苷酸进行细胞选择性端粒损伤治疗弥漫性大B细胞淋巴瘤
Synergistic effects of the Aβ/fibrinogen complex on synaptotoxicity, neuroinflammation, and blood-brain barrier damage in Alzheimer's disease models.
Aβ/纤维蛋白原复合物对阿尔茨海默病模型中的突触毒性、神经炎症和血脑屏障损伤的协同作用
Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein
联合使用upadacitinib治疗可消除肿瘤靶向IL-2融合蛋白的全身毒性
- 1
- 2
- 3
- 4
- 5
- 6
- 12